JP2004518726A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004518726A5 JP2004518726A5 JP2002564511A JP2002564511A JP2004518726A5 JP 2004518726 A5 JP2004518726 A5 JP 2004518726A5 JP 2002564511 A JP2002564511 A JP 2002564511A JP 2002564511 A JP2002564511 A JP 2002564511A JP 2004518726 A5 JP2004518726 A5 JP 2004518726A5
- Authority
- JP
- Japan
- Prior art keywords
- benzo
- trioxo
- ylmethyl
- methyl
- thiadiazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 pyridin-4-ylmethyl Chemical group 0.000 claims 68
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000005711 Benzoic acid Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 239000004305 biphenyl Substances 0.000 claims 4
- 235000010290 biphenyl Nutrition 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 claims 3
- HFFOEZMCRCHXFB-UHFFFAOYSA-N 2-benzyl-4-methyl-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazine-7-carboxylic acid Chemical compound O=S1(=O)C2=CC(C(O)=O)=CC=C2N(C)C(=O)N1CC1=CC=CC=C1 HFFOEZMCRCHXFB-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- MVOIDJGBNQHLEL-UHFFFAOYSA-N 2-benzyl-N-[(4-methoxyphenyl)methyl]-4-methyl-1,1,3-trioxo-1lambda6,2,4-benzothiadiazine-7-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC=CC=2)S2(=O)=O)C2=C1 MVOIDJGBNQHLEL-UHFFFAOYSA-N 0.000 claims 2
- DDKGNTZMSSWMOH-UHFFFAOYSA-N 2-benzyl-n-[(3-methoxyphenyl)methyl]-4-methyl-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazine-7-carboxamide Chemical compound COC1=CC=CC(CNC(=O)C=2C=C3S(=O)(=O)N(CC=4C=CC=CC=4)C(=O)N(C)C3=CC=2)=C1 DDKGNTZMSSWMOH-UHFFFAOYSA-N 0.000 claims 2
- BKIVBSPSTHHNTI-UHFFFAOYSA-N C1=CC(S(=O)(=O)NC)=CC=C1CN1S(=O)(=O)C2=CC(C(=O)NCC=3C=CC(OC)=CC=3)=CC=C2N(C)C1=O Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1CN1S(=O)(=O)C2=CC(C(=O)NCC=3C=CC(OC)=CC=3)=CC=C2N(C)C1=O BKIVBSPSTHHNTI-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 239000005973 Carvone Substances 0.000 claims 2
- 102100027995 Collagenase 3 Human genes 0.000 claims 2
- 108050005238 Collagenase 3 Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- QWFRIMMPHYDGBD-UHFFFAOYSA-N n-benzyl-4-methyl-2-[(4-methylsulfonylphenyl)methyl]-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazine-7-carboxamide Chemical compound O=S1(=O)C2=CC(C(=O)NCC=3C=CC=CC=3)=CC=C2N(C)C(=O)N1CC1=CC=C(S(C)(=O)=O)C=C1 QWFRIMMPHYDGBD-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- FSUOAMRHLSUANL-UHFFFAOYSA-N tert-butyl 4-[[7-(benzylcarbamoyl)-4-methyl-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazin-2-yl]methyl]benzoate Chemical compound O=S1(=O)C2=CC(C(=O)NCC=3C=CC=CC=3)=CC=C2N(C)C(=O)N1CC1=CC=C(C(=O)OC(C)(C)C)C=C1 FSUOAMRHLSUANL-UHFFFAOYSA-N 0.000 claims 2
- GRRIMVWABNHKBX-UHFFFAOYSA-N (3-methoxyphenyl)methanamine Chemical compound COC1=CC=CC(CN)=C1 GRRIMVWABNHKBX-UHFFFAOYSA-N 0.000 claims 1
- WZMNUGKJRDYNGO-UHFFFAOYSA-N 2-[(4-aminophenyl)methyl]-n-[(4-methoxyphenyl)methyl]-4-methyl-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazine-7-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC(N)=CC=2)S2(=O)=O)C2=C1 WZMNUGKJRDYNGO-UHFFFAOYSA-N 0.000 claims 1
- ULSPUXOZEHBOFQ-UHFFFAOYSA-N 2-[(4-cyanophenyl)methyl]-N-[(4-methoxyphenyl)methyl]-4-methyl-1,1,3-trioxo-1lambda6,2,4-benzothiadiazine-7-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC(=CC=2)C#N)S2(=O)=O)C2=C1 ULSPUXOZEHBOFQ-UHFFFAOYSA-N 0.000 claims 1
- JLSXCZVJXDOMJO-UHFFFAOYSA-N 2-[4-[[7-[(4-methoxyphenyl)methylcarbamoyl]-4-methyl-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazin-2-yl]methyl]phenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC(CC(O)=O)=CC=2)S2(=O)=O)C2=C1 JLSXCZVJXDOMJO-UHFFFAOYSA-N 0.000 claims 1
- VKZMHTAOGZYTPN-UHFFFAOYSA-N 2-[[4-[[7-[(4-methoxyphenyl)methylcarbamoyl]-4-methyl-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazin-2-yl]methyl]benzoyl]amino]-3-methylbutanoic acid Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC(=CC=2)C(=O)NC(C(C)C)C(O)=O)S2(=O)=O)C2=C1 VKZMHTAOGZYTPN-UHFFFAOYSA-N 0.000 claims 1
- KZMCTEXOXBHFKO-UHFFFAOYSA-N 2-benzyl-N-[(2-methoxypyridin-4-yl)methyl]-4-methyl-1,1,3-trioxo-1lambda6,2,4-benzothiadiazine-7-carboxamide Chemical compound C1=NC(OC)=CC(CNC(=O)C=2C=C3S(=O)(=O)N(CC=4C=CC=CC=4)C(=O)N(C)C3=CC=2)=C1 KZMCTEXOXBHFKO-UHFFFAOYSA-N 0.000 claims 1
- PQRVGRQVNOIPOW-UHFFFAOYSA-N 2-benzyl-N-[(4-fluorophenyl)methyl]-4-methyl-1,1,3-trioxo-1lambda6,2,4-benzothiadiazine-7-carboxamide Chemical compound O=S1(=O)C2=CC(C(=O)NCC=3C=CC(F)=CC=3)=CC=C2N(C)C(=O)N1CC1=CC=CC=C1 PQRVGRQVNOIPOW-UHFFFAOYSA-N 0.000 claims 1
- MQZUPFIZRPUPEB-UHFFFAOYSA-N 2-benzyl-n-[[4-[2-(tert-butylsulfamoyl)ethyl]phenyl]methyl]-4-methyl-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazine-7-carboxamide Chemical compound O=S1(=O)C2=CC(C(=O)NCC=3C=CC(CCS(=O)(=O)NC(C)(C)C)=CC=3)=CC=C2N(C)C(=O)N1CC1=CC=CC=C1 MQZUPFIZRPUPEB-UHFFFAOYSA-N 0.000 claims 1
- FGKOGDBNWDQXPH-UHFFFAOYSA-N 4-[[7-[(3-methoxyphenyl)methylcarbamoyl]-4-methyl-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazin-2-yl]methyl]benzoic acid Chemical compound COC1=CC=CC(CNC(=O)C=2C=C3S(=O)(=O)N(CC=4C=CC(=CC=4)C(O)=O)C(=O)N(C)C3=CC=2)=C1 FGKOGDBNWDQXPH-UHFFFAOYSA-N 0.000 claims 1
- BPXURTQRNAEHJA-UHFFFAOYSA-N 4-[[7-[(4-fluorophenyl)methylcarbamoyl]-4-methyl-1,1,3-trioxo-1lambda6,2,4-benzothiadiazin-2-yl]methyl]benzoic acid Chemical compound O=S1(=O)C2=CC(C(=O)NCC=3C=CC(F)=CC=3)=CC=C2N(C)C(=O)N1CC1=CC=C(C(O)=O)C=C1 BPXURTQRNAEHJA-UHFFFAOYSA-N 0.000 claims 1
- ZKDKZVIVBGMQLH-UHFFFAOYSA-N 4-[[7-[(4-methoxyphenyl)methylcarbamoyl]-4-methyl-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazin-2-yl]methyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC(=CC=2)C(O)=O)S2(=O)=O)C2=C1 ZKDKZVIVBGMQLH-UHFFFAOYSA-N 0.000 claims 1
- ZYMYUJQQKRKUEV-UHFFFAOYSA-N C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=C3C=CC=CC3=CC=2)S2(=O)=O)C2=C1 Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=C3C=CC=CC3=CC=2)S2(=O)=O)C2=C1 ZYMYUJQQKRKUEV-UHFFFAOYSA-N 0.000 claims 1
- CYPADTCNYBYDOW-UHFFFAOYSA-N C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC(=CC=2)C(N)=O)S2(=O)=O)C2=C1 Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC(=CC=2)C(N)=O)S2(=O)=O)C2=C1 CYPADTCNYBYDOW-UHFFFAOYSA-N 0.000 claims 1
- SKVSNLASBUVVQE-UHFFFAOYSA-N C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)S2(=O)=O)C2=C1 Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)S2(=O)=O)C2=C1 SKVSNLASBUVVQE-UHFFFAOYSA-N 0.000 claims 1
- BLQPTMAEAGUBHI-UHFFFAOYSA-N CN1C2=C(C=C(C=C2)C(=O)NCC3=CC=C(C=C3)OC)S(=O)(=O)N(C1=O)CC4=CN=NO4 Chemical compound CN1C2=C(C=C(C=C2)C(=O)NCC3=CC=C(C=C3)OC)S(=O)(=O)N(C1=O)CC4=CN=NO4 BLQPTMAEAGUBHI-UHFFFAOYSA-N 0.000 claims 1
- UYKZWRNDVPKXAP-UHFFFAOYSA-N COC1=CC=C(CNC(=O)C2=CC3=C(N(C(N(S3(=O)=O)CCCCCC#N)=O)C)C=C2)C=C1 Chemical compound COC1=CC=C(CNC(=O)C2=CC3=C(N(C(N(S3(=O)=O)CCCCCC#N)=O)C)C=C2)C=C1 UYKZWRNDVPKXAP-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- FQGNPTLEWZKORY-UHFFFAOYSA-N N-(2,1,3-benzothiadiazol-5-ylmethyl)-2-benzyl-4-methyl-1,1,3-trioxo-1lambda6,2,4-benzothiadiazine-7-carboxamide Chemical compound O=S1(=O)C2=CC(C(=O)NCC3=CC4=NSN=C4C=C3)=CC=C2N(C)C(=O)N1CC1=CC=CC=C1 FQGNPTLEWZKORY-UHFFFAOYSA-N 0.000 claims 1
- KKLIHULDLTVBBE-UHFFFAOYSA-N N-[(4-methoxyphenyl)methyl]-4-methyl-1,1,3-trioxo-2-(1-phenylethyl)-1lambda6,2,4-benzothiadiazine-7-carboxamide Chemical compound COC1=CC=C(CNC(=O)C2=CC3=C(C=C2)N(C)C(=O)N(C(C)C2=CC=CC=C2)S3(=O)=O)C=C1 KKLIHULDLTVBBE-UHFFFAOYSA-N 0.000 claims 1
- CQFKCXOGSUEOPH-UHFFFAOYSA-N N-[(4-methoxyphenyl)methyl]-4-methyl-1,1,3-trioxo-2-[[4-(piperidine-1-carbonyl)phenyl]methyl]-1lambda6,2,4-benzothiadiazine-7-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC(=CC=2)C(=O)N2CCCCC2)S2(=O)=O)C2=C1 CQFKCXOGSUEOPH-UHFFFAOYSA-N 0.000 claims 1
- YHARJTWBNSCQSF-UHFFFAOYSA-N N-[(4-methoxyphenyl)methyl]-4-methyl-1,1,3-trioxo-2-pent-2-ynyl-1lambda6,2,4-benzothiadiazine-7-carboxamide Chemical compound CCC#CCN1C(=O)N(C)C2=C(C=C(C=C2)C(=O)NCC2=CC=C(OC)C=C2)S1(=O)=O YHARJTWBNSCQSF-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- FJMHEXIZSUWPRC-UHFFFAOYSA-N benzyl 2-benzyl-4-methyl-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazine-7-carboxylate Chemical compound O=S1(=O)C2=CC(C(=O)OCC=3C=CC=CC=3)=CC=C2N(C)C(=O)N1CC1=CC=CC=C1 FJMHEXIZSUWPRC-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000005394 methallyl group Chemical group 0.000 claims 1
- LUKQNVONMAWTPU-UHFFFAOYSA-N methyl 4-[[7-[(4-fluorophenyl)methylcarbamoyl]-4-methyl-1,1,3-trioxo-1lambda6,2,4-benzothiadiazin-2-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1S(=O)(=O)C2=CC(C(=O)NCC=3C=CC(F)=CC=3)=CC=C2N(C)C1=O LUKQNVONMAWTPU-UHFFFAOYSA-N 0.000 claims 1
- QHZDHVOPACDKKU-UHFFFAOYSA-N n,2-dibenzyl-4-methyl-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazine-7-carboxamide Chemical compound O=S1(=O)C2=CC(C(=O)NCC=3C=CC=CC=3)=CC=C2N(C)C(=O)N1CC1=CC=CC=C1 QHZDHVOPACDKKU-UHFFFAOYSA-N 0.000 claims 1
- UOQDSWFJWJDQHW-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-2h-1,2,4-benzothiadiazine-7-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N=CNS2)C2=C1 UOQDSWFJWJDQHW-UHFFFAOYSA-N 0.000 claims 1
- WMWRSTGEWPFAJA-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-4-methyl-1,1,3-trioxo-2-[[4-(2h-tetrazol-5-yl)phenyl]methyl]-1$l^{6},2,4-benzothiadiazine-7-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC(=CC=2)C2=NNN=N2)S2(=O)=O)C2=C1 WMWRSTGEWPFAJA-UHFFFAOYSA-N 0.000 claims 1
- INQFEVWRGOYPHE-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-4-methyl-2-(3-methylbut-2-enyl)-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazine-7-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=C(C)C)S2(=O)=O)C2=C1 INQFEVWRGOYPHE-UHFFFAOYSA-N 0.000 claims 1
- WDAYTKNRLFKESC-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-4-methyl-2-[(4-nitrophenyl)methyl]-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazine-7-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC(=CC=2)[N+]([O-])=O)S2(=O)=O)C2=C1 WDAYTKNRLFKESC-UHFFFAOYSA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- IPDBNPDTSNKARK-UHFFFAOYSA-N tert-butyl 4-[[7-[(4-methoxyphenyl)methylcarbamoyl]-4-methyl-1,1,3-trioxo-1$l^{6},2,4-benzothiadiazin-2-yl]methyl]benzoate Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(C)C(=O)N(CC=2C=CC(=CC=2)C(=O)OC(C)(C)C)S2(=O)=O)C2=C1 IPDBNPDTSNKARK-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26878201P | 2001-02-14 | 2001-02-14 | |
| PCT/IB2002/000083 WO2002064578A1 (en) | 2001-02-14 | 2002-01-11 | Benzo thiadiazine matrix metalloproteinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004518726A JP2004518726A (ja) | 2004-06-24 |
| JP2004518726A5 true JP2004518726A5 (enExample) | 2005-07-28 |
Family
ID=23024450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002564511A Abandoned JP2004518726A (ja) | 2001-02-14 | 2002-01-11 | ベンゾチアジアジンマトリックスメタロプロテイナーゼ阻害剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6656932B2 (enExample) |
| EP (1) | EP1368327B1 (enExample) |
| JP (1) | JP2004518726A (enExample) |
| AT (1) | ATE280164T1 (enExample) |
| BR (1) | BR0207865A (enExample) |
| CA (1) | CA2433075A1 (enExample) |
| DE (1) | DE60201665T2 (enExample) |
| DO (1) | DOP2002000336A (enExample) |
| ES (1) | ES2231708T3 (enExample) |
| GT (1) | GT200200016A (enExample) |
| HN (1) | HN2002000227A (enExample) |
| MX (1) | MXPA03005870A (enExample) |
| PA (1) | PA8538501A1 (enExample) |
| PE (1) | PE20020953A1 (enExample) |
| TN (1) | TNSN02013A1 (enExample) |
| UY (1) | UY27155A1 (enExample) |
| WO (1) | WO2002064578A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
| US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| EP1434585A1 (en) | 2001-10-12 | 2004-07-07 | Warner-Lambert Company LLC | Alkyne matrix metalloproteinase inhibitors |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
| CA2492391A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| CA2495432A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| EP1534274A1 (en) * | 2002-07-17 | 2005-06-01 | Warner-Lambert Company LLC | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| EP1536786A1 (en) * | 2002-07-17 | 2005-06-08 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| WO2004014365A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
| BR0313384A (pt) | 2002-08-13 | 2005-07-12 | Warner Lambert Co | Derivados de cromona como inibidores de metaloproteinases de matriz |
| BR0313460A (pt) * | 2002-08-13 | 2005-07-05 | Warner Lambert Co | Derivados de naftaleno como inibidores de metaloproteinase da matriz |
| AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
| WO2004014866A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| WO2004014909A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| CA2492019A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Isoquinoline derivatives as matrix metalloproteinase inhibitors |
| PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| AU2003250471A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
| AU2003249534A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors |
| WO2004014869A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
| WO2004014384A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| AU2003253165A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| EP1537098A1 (en) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company LLC | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| AU2003249477A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
| US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
| US7247654B2 (en) | 2003-06-04 | 2007-07-24 | Bristol-Myers Squibb Company | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
| EP1680125A1 (en) * | 2003-07-02 | 2006-07-19 | Warner-Lambert Company LLC | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
| US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
| US7570259B2 (en) | 2004-06-01 | 2009-08-04 | Intel Corporation | System to manage display power consumption |
| EP1828152B1 (en) | 2004-12-08 | 2008-08-20 | Bristol-Myers Squibb Company | Heterocyclic compounds as inhibitors of factor viia |
| EP1860098B1 (en) | 2005-03-16 | 2012-11-14 | Toyama Chemical Co., Ltd. | Novel anthranilic acid derivative or salt thereof |
| AU2010266018B2 (en) | 2009-06-25 | 2014-01-09 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| MX358344B (es) | 2011-03-18 | 2018-08-15 | Alkermes Pharma Ireland Ltd | Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan. |
| EP2827868B8 (en) | 2012-03-19 | 2019-12-18 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| NZ630428A (en) | 2012-03-19 | 2017-02-24 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising benzyl alcohol |
| AU2013235523B9 (en) | 2012-03-19 | 2018-01-04 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
| WO2014080285A2 (en) | 2012-09-19 | 2014-05-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| CN110368360A (zh) | 2014-03-20 | 2019-10-25 | 奥克梅斯制药爱尔兰有限公司 | 具有增加的注射速度的阿立哌唑制剂 |
| WO2019173230A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN111454232B (zh) * | 2020-05-30 | 2021-11-23 | 南方医科大学 | 一种1,3,4-噻二嗪类化合物及其应用 |
| CN113773277B (zh) * | 2021-09-18 | 2023-12-05 | 兰州大学 | 一种4h-1,2,4-苯并噻二嗪-1,1-二氧化物衍生物的合成方法 |
| IL319671A (en) | 2022-09-26 | 2025-05-01 | Edgewise Therapeutics Inc | 4,1-Dihydroquinazolinone compounds and their uses |
| WO2024206347A1 (en) * | 2023-03-27 | 2024-10-03 | Edgewise Therapeutics, Inc. | Fused thiadiazine dioxide compounds and uses thereof |
| EP4688756A1 (en) | 2023-03-27 | 2026-02-11 | Edgewise Therapeutics, Inc. | Quinazoline dione compounds and uses thereof |
| CN121194963A (zh) | 2023-03-27 | 2025-12-23 | 艾知怀斯治疗学公司 | 喹啉酮酰胺类化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242443B1 (en) * | 1996-06-21 | 2001-06-05 | Novo Nordisk Ais | 1,2,4-benzothiadiazine derivatives, their preparation and use |
| NZ334897A (en) * | 1996-12-09 | 2001-02-23 | Warner Lambert Co | Medicaments for treating and preventing heart failure and ventricular dilatation |
| DE69832374D1 (de) * | 1997-04-28 | 2005-12-22 | Us Health | Cyclin abhängige kinase(cdk)4 hemmer und deren verwendung zur behandlung von krebs |
| JPH11199512A (ja) | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用 |
| AU4932299A (en) | 1999-07-30 | 2001-02-19 | Yoshikane Ikitake | Reciprocating vane type rotary internal combustion engine |
| PA8498701A1 (es) | 1999-08-12 | 2002-08-26 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
| US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
| EP1138680A1 (en) | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
| EE200300195A (et) | 2000-10-26 | 2003-10-15 | Pfizer Products Inc. | Pürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid |
| EP1332146A2 (en) | 2000-10-26 | 2003-08-06 | Pfizer Products Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| PA8539301A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
-
2002
- 2002-01-11 AT AT02740094T patent/ATE280164T1/de not_active IP Right Cessation
- 2002-01-11 ES ES02740094T patent/ES2231708T3/es not_active Expired - Lifetime
- 2002-01-11 JP JP2002564511A patent/JP2004518726A/ja not_active Abandoned
- 2002-01-11 WO PCT/IB2002/000083 patent/WO2002064578A1/en not_active Ceased
- 2002-01-11 BR BR0207865-1A patent/BR0207865A/pt not_active IP Right Cessation
- 2002-01-11 CA CA002433075A patent/CA2433075A1/en not_active Abandoned
- 2002-01-11 MX MXPA03005870A patent/MXPA03005870A/es unknown
- 2002-01-11 EP EP02740094A patent/EP1368327B1/en not_active Expired - Lifetime
- 2002-01-11 DE DE60201665T patent/DE60201665T2/de not_active Expired - Fee Related
- 2002-02-01 DO DO2002000336A patent/DOP2002000336A/es unknown
- 2002-02-05 PA PA20028538501A patent/PA8538501A1/es unknown
- 2002-02-07 GT GT200200016A patent/GT200200016A/es unknown
- 2002-02-08 UY UY27155A patent/UY27155A1/es not_active Application Discontinuation
- 2002-02-11 HN HN2002000227A patent/HN2002000227A/es unknown
- 2002-02-12 PE PE2002000109A patent/PE20020953A1/es not_active Application Discontinuation
- 2002-02-13 TN TNTNSN02013A patent/TNSN02013A1/fr unknown
- 2002-02-13 US US10/074,646 patent/US6656932B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004518726A5 (enExample) | ||
| ES2534392T3 (es) | Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso | |
| JP6505153B2 (ja) | がん細胞の転移を予防するための化合物、組成物および方法 | |
| JP2004517080A5 (enExample) | ||
| KR100706735B1 (ko) | ｈＰＰＡＲ 알파 활성제로서 치환된 옥사졸 및 티아졸유도체 | |
| AU2011312203C1 (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| KR101154163B1 (ko) | 티아졸 유도체 및 ｖａｐ-1 저해제로서의 용도 | |
| JP2008540574A5 (enExample) | ||
| RU2003112691A (ru) | Бензамидные соединения в качестве ингибиторов секреции аро в | |
| JP2008513499A5 (enExample) | ||
| JP2004534035A5 (enExample) | ||
| RU2000105266A (ru) | Производные 1-(n-фениламиноалкил)-пиперазина, замещенные в положении 2 фенильного кольца | |
| WO2002002542A1 (fr) | Compose annulaire a cinq chainons | |
| EP2650287A1 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
| JPWO2002002542A1 (ja) | ５員環化合物 | |
| RU2415846C2 (ru) | Производные, имеющие активность агонистов ppar-рецепторов | |
| CA2729649A1 (en) | Thiazopyrimidinones and uses thereof | |
| CZ304035B6 (cs) | N-fenylarylsulfonamidová sloucenina, farmaceutická kompozice obsahující tuto slouceninu jako úcinnou slozku, syntetický meziprodukt pro tuto slouceninu a zpusob jeho prípravy | |
| RU2348616C2 (ru) | Новые пиперидины в качестве модуляторов хемокинов (ccr) | |
| RU2007130152A (ru) | Производные 1, 1-диоксидов изотиазол-3(2h)-онов в качестве модуляторов печеночных х-рецепторов | |
| CN101506180B (zh) | 人蛋白酪氨酸磷酸酶抑制剂及使用方法 | |
| JP2003192591A (ja) | ５員環化合物からなる医薬 | |
| JP2004536788A5 (enExample) | ||
| RU2002101136A (ru) | Средства для лечения и профилактики неоплазм | |
| TR202016444A2 (tr) | İlaç etki̇n maddesi̇ olarak kullanima uygun bi̇stri̇fluorometi̇lfeni̇l türevleri̇ ve bunlarin sentezlenmesi̇ i̇çi̇n yöntem |